Cytologic endometrial surveillance in tamoxifen-treated women

The authors report the results of a study conducted on 136 patients affected by breast cancer under treatment with tamoxifen at a daily dose of 20 mg who underwent a strict follow-up including endometrial surveillance. The cytologic evaluation of the endometrium was performed on smears obtained by the endocyte sampling. The results were in accordance with what is reported in the literature. Forty cases presented with hyperplasia which was atypical in two cases. Only in one case did histology show a well differentiated adenocarcinoma. In 25 cases the endometrium resulted to be proliferative in accordance with the effect of tamoxifen, while the remaining 67 cases were atrophic. The investigation was not possible in four cases due to stenosis. In our study the endocyte sampler resulted to be an economic, simple and painless cytologic device, suitable for clinical use because of its low incidence of false positives.

Tamoxifen; Endocyte sampling; Hyperplasia; Adenocarcinoma

[1] Jordan V. C.: "Overview from International Conference on longterm Tamoxifen therapy for breast cancer". J. Nat. Cancer Inst., 1990, 84, 231.

[2] Maltoni M. Derni S., Innocenti M. P., Casadei Giunchi D., Amadori G.: "Tamoxifen: farmacologia ed impegno clinico" Argornenti di Oncologia, 1991, 12, 293.

[3] Neven P., Vernaeve H.: "Guidelines for monitoring patients taking tamoxifen treatment". Drug. Saf, 2000, 22, 1.

[4] Zarbo G., Caruso G., Tammiti M., Caruso S., Zarbo R.: "The effects of tamoxifen therapy on the endometrium". Eur. J. Gynaecol. Oneal., 2000, 21, 86.

[5] Cardosi R. J., Fiorica J. V.: "Surveillance of the endometrium in tamoxifen treated women". Curr. Opin. Obstet. Gynecol., 2000, 12, 27.

[6] Love C. D., Muir B.B., Scimgeour J. B., Leonard R. C., DilIon P., Dixon J.M.: "Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evalutaion of the role of endometrial screening". J. Clin. Oneal., 1999 Jul., 17, 2050.

[7] Canavan T. P., Doshi N. R.: "Endometrial cancer". Am. Fam. Phys., 1999, 59, 3069.

[8] Suh-Burgmann E. J., Goodman A.: "Surveillance for endometrial cancer in women receiving tamoxifen". Ann. Intern. Med., 1999, 131, 127.

[9] Seoud M., Shamseddine A., Khalil A., Salem Z., Saghir N., Biakhazi K. et al.: "Tamoxifen and endometrial pathologies: a prospective study". Gynecol. Oneal., 1999, 75, 15.

[10] Gail M. H., Costantino J.P., Bryant J., Croyle R., Freedman L., Helzlsouer K., Vogel V.: "Weighing the risks and benefits of tamoxifen treatment of preventing breast cancer". J. Natl. Cancer Inst., 1999, 91, 1829.

[11] Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C.: "Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study". Lancet, 1998, 352, 93.

[12] Berliere M., Charles A., Galant C., Donnez J.: "Uterine side effects of tamoxifen: a need for systematic pretreatment screening". Obstet. Gynecol., 1998, 91, 40.

[13] Powles T. J., Bourne T., Athanasiour S., Chang J., Grubock K., Ashley S. et al.: "The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo". Br. J. Cancer, 1998, 78, 272.

[14] Tsuda H., Kawabata M., Yamamoto K., Inoue T., Umesaki N.: "Prospective study to compare endometrial cytology and transvaginal ultrasonography for identification of endometrial malignancies". Gynecol. Oneal., 1998, 68, 307.

[15] Barakat R. R.: "Benign and hyperplastic endometrial changes associated with tamoxifen use". Oncol. Hunting!, 1997, 11 (Suppl. 1), 35.

[16] Kufahl J., Perdesen I., Sinderbeg-Erikesen P., Helkjaer P. E., Larsen L. G., Jensen K. L. et al.: "Transvaginal ultrasound, endometrial cytology sampled by Gynoscann and histology obtained by Uterine Explora Curette compared to the histology of the uterine specimen. A prospective study in pre-and postmenopausal women undergoing elective hysterectomy". Acta Obstet. Gynecol. Scand., 1997, 76, 790.

[17] Cuenca R. E., Giachino J., Arredondo M.A., Hempling R., Edge S. B.: "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use". Cancer, 1996, 77, 2058.

[18] Porrazzi L. C., Quarto F., Maiello F. M., De Falco M. L., Antonucci T.:'The value of endometrial cytology by scraping in I, 798 cases: screening in asymptomatic women and diagnosis in symptomatic ones". Diagn. Cythopathol., 1987, 3, 112.

[19] Ferenczy A., Gelfand M. M.: "Outpatient endometrial samphng with Endocyte: comparative study of its effectiveness with endometrial biopsy". Obstet. Gynecol., I 984, 63, 295.

[20] Yazigi R., Sanchez J., Duarte I., Verni J.: "Cytologic detection of endometrial carcinoma by the endocyte technique". Gynecol. Oncol., 1983, 16, 346.

[21] Byrne A. J.: "Endocyte endometrial smears in the cytodiagnosis of endometrial carcinoma". Acta Cytol., 1990, 34, 373.

[22] Carcangiu M. L., Chambers J. T.: "Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival". Int. J. Gynecol. Pathol., 1995, 14, 30.

[23] Carcangiu M. L., Chambers J. T.: "Uterine papillary serous carCJnoma: a study on 108 cases with emphasis on the prognostic significance of associated endometroid carcinoma, absence of invasion, and concomitant ovarian carcinoma". Gynecol. Oncol., 1992, 47, 298.